Get the Stockscreener App
25.80
3.98%
-1.07
After Hours:
27.28
1.48
+5.74%
Neurogene Inc Stock (NGNE) Latest News
Neurogene Inc. sees significant stock purchases by Samsara BioCapital - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Insider Buying: Christine Cvijic Acquires 24,000 Shares of Neuro - GuruFocus.com
Neurogene president buys $491,400 in company stock By Investing.com - Investing.com Nigeria
Neurogene president buys $491,400 in company stock - Investing.com
Neurogene CEO Rachel McMinn acquires $968,999 in stock - Investing.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc.NGNE - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation - AccessWire
Neurogene retains stock target, buy rating amid Rett syndrome trial data - Investing.com
Neurogene retains stock target, buy rating amid Rett syndrome trial data By Investing.com - Investing.com South Africa
HC Wainwright Reaffirms Buy Rating for Neurogene (NASDAQ:NGNE) - MarketBeat
Patient dies in Neurogene trial - The Pharma Letter
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect - AccessWire
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week - MSN
Jennison Associates LLC Makes New Investment in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Neurogene patient dies in drug trial, stock surges after FDA says ‘use lower dose’ - Mugglehead
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose - MedCity News
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Stockholders to Inquire about Securities Investigation - AccessWire
Patient dies in Neurogene’s Phase I/II Rett syndrome trial - Yahoo Finance
Neurogene drops high-dose arm in Rett study after death - pharmaphorum
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial - Yahoo Finance
Neurogene reports patient death in Rett syndrome trial - Investing.com
Neurogene reports patient death in Rett syndrome trial By Investing.com - Investing.com Australia
Neurogene Adjusts Clinical Trial After Setback - TipRanks
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation - AccessWire
Leerink Partnrs Forecasts Reduced Earnings for Neurogene - MarketBeat
FY2024 EPS Estimates for Neurogene Cut by William Blair - MarketBeat
FY2024 EPS Estimates for Neurogene Raised by HC Wainwright - MarketBeat
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene price target lowered to $45 from $60 at BMO Capital - TipRanks
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More - BioSpace
Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles - TipRanks
Neurogene's (NGNE) Outperform Rating Reiterated at William Blair - MarketBeat
Neurogene’s Value Tanks On Gene Therapy Side-Effect Details - Citeline
Neurogene (NASDAQ:NGNE) Receives Buy Rating from HC Wainwright - MarketBeat
Neurogene: Q3 Earnings Snapshot - CT Insider
Neurogene Inc reports results for the quarter ended September 30Earnings Summary - XM
Neurogene Inc (NGNE) Quarterly 10-Q Report - Quartz
Neurogene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Neurogene Reports Promising Rett Syndrome Trial Data Despite Wider Q3 Loss | NGNE Stock News - StockTitan
Stock Market News: QMMM Holdings plunges by 69% whereas Neurogene falls by 44.05% during mid day trading - Business Upturn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect - AccessWire
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Neurogene stock plunges 36% on NGN-401 study update (NASDAQ:NGNE) - Seeking Alpha
Neurogene falls again on Rett gene therapy side effects - pharmaphorum
NGNENeurogene, Inc. Latest Stock News & Market Updates - StockTitan
Neurogene Drops High-Dose Cohort of Gene-Therapy Study for Rett Syndrome - MarketWatch
Neurogene Adjusts NGN-401 Trial After Adverse Event - TipRanks
Neurogene Halts High-Dose Rett Syndrome Trial After Critical Safety Event, FDA Clears Low Dose | NGNE Stock News - StockTitan
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Janus Henderson Group PLC's Strategic Reduction in Neurogene Inc Holdings - GuruFocus.com
Neurogene To Report Rett Syndrome Trial Data Next WeekStock Up 90% In 8 Months - RTTNews
United States shares lower at close of trade; Dow Jones Industrial Average down 0.86% - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation - AccessWire
RTW INVESTMENTS, LP Expands Stake in Neurogene Inc - GuruFocus.com
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):